{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:22:48Z","timestamp":1792790568784,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["2220781-601"],"award-info":[{"award-number":["2220781-601"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["2220781-601"],"award-info":[{"award-number":["2220781-601"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["2220781-601"],"award-info":[{"award-number":["2220781-601"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["2220781-601"],"award-info":[{"award-number":["2220781-601"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001840","name":"Icelandic Centre for Research","doi-asserted-by":"publisher","award":["2220781-601"],"award-info":[{"award-number":["2220781-601"]}],"id":[{"id":"10.13039\/501100001840","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The research work at biotx.ai GmbH is supported by the Investitionsbank des Landes Brandenburg (ILB), the European Regional Development Fund (ERDF), and the European Social Fund+ (ESF+).","id":[{"id":"https:\/\/ror.org\/048snh465","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    ADHD is a chronic neurodevelopmental disorder that significantly affects life outcomes, and current treatments often have adverse side effects, high abuse potential, and a 25% non-response rate, highlighting the need for new therapeutics. This study investigates amlodipine, an L-type calcium channel blocker, as a potential foundation for developing a novel ADHD treatment by integrating findings from animal models and human genetic data. Amlodipine reduced hyperactivity in SHR rats and decreased both hyperactivity and impulsivity in\n                    <jats:italic>adgrl3.1<\/jats:italic>\n                    \u2212\/\u2212 zebrafish. It also crosses the blood-brain barrier, reducing telencephalic activation. Crucially, Mendelian Randomization analysis linked ADHD to genetic variations in L-type calcium channel subunits (\u03b11-C; CACNA1C, \u03b21; CACNB1, \u03b12\u03b43; CACNA2D3) targeted by amlodipine, while polygenic risk score analysis showed symptom mitigation in individuals with high ADHD genetic liability. With its well-tolerated profile and efficacy across species, supported by genetic evidence, amlodipine shows potential to be refined and developed into a novel treatment for ADHD.\n                  <\/jats:p>","DOI":"10.1038\/s41386-025-02062-x","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T11:33:07Z","timestamp":1739532787000},"page":"1145-1155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records"],"prefix":"10.1038","volume":"50","author":[{"given":"Haraldur","family":"\u00deorsteinsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannes A.","family":"Baukmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildur S.","family":"Sveinsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar \u00de.","family":"Halld\u00f3rsd\u00f3ttir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Grzymala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4787-7400","authenticated-orcid":false,"given":"Courtney","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Rolfe-Tarrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7172-5231","authenticated-orcid":false,"given":"Matthew O.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin L.","family":"Cope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles N. J.","family":"Ravarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco F.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5931-8422","authenticated-orcid":false,"given":"Karl \u00c6.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2062_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1146\/annurev-devpsych-060320-093413","volume":"2","author":"JT Nigg","year":"2020","unstructured":"Nigg JT, Sibley MH, Thapar A, Karalunas SL. Development of ADHD: etiology, heterogeneity, and early life course. Annu Rev Dev Psychol. 2020;2:559\u201383.","journal-title":"Annu Rev Dev Psychol"},{"key":"2062_CR2","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","volume":"179","author":"MH Sibley","year":"2022","unstructured":"Sibley MH, Arnold LE, Swanson JM, Hechtman LT, Kennedy TM, Owens E, et al. Variable patterns of remission from ADHD in the multimodal treatment study of ADHD. American Journal Psychiatry. 2022;179:142\u201351.","journal-title":"American Journal Psychiatry"},{"key":"2062_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/2045125317734977","volume":"8","author":"J Geffen","year":"2018","unstructured":"Geffen J, Forster K. Treatment of adult ADHD: a clinical perspective. Ther Adv Psychopharmacol. 2018;8:25\u201332.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2062_CR4","first-page":"192","volume":"21","author":"L Briars","year":"2016","unstructured":"Briars L, Todd T. A review of pharmacological management of attention-deficit\/hyperactivity disorder. J Pediatr Pharmacol Ther. 2016;21:192\u2013206.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"2062_CR5","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","volume":"383","author":"S Cortese","year":"2020","unstructured":"Cortese S. Pharmacologic treatment of attention deficit-hyperactivity disorder. N. Engl J Med. 2020;383:1050\u201356.","journal-title":"N. Engl J Med"},{"key":"2062_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/brainsci11010091","volume":"11","author":"PC Mamiya","year":"2021","unstructured":"Mamiya PC, Arnett AB, Stein MA. Precision medicine care in ADHD: the case for neural excitation and inhibition. Brain Sci. 2021;11:91.","journal-title":"Brain Sci"},{"key":"2062_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/s41386-022-01505-z","volume":"48","author":"HS Sveinsdottir","year":"2023","unstructured":"Sveinsdottir HS, Christensen C, Thornorsteinsson H, Lavalou P, Parker MO, Shkumatava A, et al. Novel non-stimulants rescue hyperactive phenotype in an adgrl3.1 mutant zebrafish model of ADHD. Neuropsychopharmacology. 2023;48:1155\u201363.","journal-title":"Neuropsychopharmacology"},{"key":"2062_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104494","volume":"130","author":"SL Regan","year":"2019","unstructured":"Regan SL, Hufgard JR, Pitzer EM, Sugimoto C, Hu YC, Williams MT, et al. Knockout of latrophilin-3 in Sprague-Dawley rats causes hyperactivity, hyper-reactivity, under-response to amphetamine, and disrupted dopamine markers. Neurobiol Dis. 2019;130:104494.","journal-title":"Neurobiol Dis"},{"key":"2062_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-023-02601-4","volume":"13","author":"BD Fontana","year":"2023","unstructured":"Fontana BD, Reichmann F, Tilley CA, Lavlou P, Shkumatava A, Alnassar N, et al. adgrl3.1-deficient zebrafish show noradrenaline-mediated externalizing behaviors, and altered expression of externalizing disorder-candidate genes, suggesting functional targets for treatment. Transl Psychiatry. 2023;13:304.","journal-title":"Transl Psychiatry"},{"key":"2062_CR10","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1007\/s00213-014-3439-z","volume":"231","author":"MO Parker","year":"2014","unstructured":"Parker MO, Brock AJ, Sudwarts A, Brennan CH. Atomoxetine reduces anticipatory responding in a 5-choice serial reaction time task for adult zebrafish. Psychopharmacology. 2014;231:2671\u20139.","journal-title":"Psychopharmacology"},{"key":"2062_CR11","doi-asserted-by":"publisher","first-page":"e1008489","DOI":"10.1371\/journal.pgen.1008489","volume":"15","author":"EA King","year":"2019","unstructured":"King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. PLoS Genet. 2019;15:e1008489.","journal-title":"PLoS Genet"},{"key":"2062_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ajhg.2022.12.017","volume":"110","author":"S Burgess","year":"2023","unstructured":"Burgess S, Mason AM, Grant AJ, Slob EAW, Gkatzionis A, Zuber V, et al. Using genetic association data to guide drug discovery and development: review of methods and applications. Am J Hum Genet. 2023;110:195\u2013214.","journal-title":"Am J Hum Genet"},{"key":"2062_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3389\/fnsys.2013.00065","volume":"7","author":"MO Parker","year":"2013","unstructured":"Parker MO, Ife D, Ma J, Pancholi M, Smeraldi F, Straw C, et al. Development and automation of a test of impulse control in zebrafish. Front Syst Neurosci. 2013;7:65.","journal-title":"Front Syst Neurosci"},{"key":"2062_CR14","doi-asserted-by":"publisher","first-page":"e0259753","DOI":"10.1371\/journal.pone.0259753","volume":"17","author":"HS Sveinsdottir","year":"2022","unstructured":"Sveinsdottir HS, Decker A, Christensen C, Lucena PB, Thornorsteinsson H, Richert E, et al. Motility phenotype in a zebrafish vmat2 mutant. PLoS One. 2022;17:e0259753.","journal-title":"PLoS One"},{"key":"2062_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9:676\u201382.","journal-title":"Nat Methods"},{"key":"2062_CR16","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41586-022-05473-8","volume":"613","author":"MI Kurki","year":"2023","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613:508\u201318.","journal-title":"Nature"},{"key":"2062_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41588-022-01285-8","volume":"55","author":"D Demontis","year":"2023","unstructured":"Demontis D, Walters GB, Athanasiadis G, Walters R, Therrien K, Nielsen TT, et al. Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic architecture and implicate several cognitive domains. Nat Genet. 2023;55:198\u2013208.","journal-title":"Nat Genet"},{"key":"2062_CR18","doi-asserted-by":"publisher","first-page":"e1001779","DOI":"10.1371\/journal.pmed.1001779","volume":"12","author":"C Sudlow","year":"2015","unstructured":"Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12:e1001779.","journal-title":"PLoS Med"},{"key":"2062_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36231-7","volume":"14","author":"H Julkunen","year":"2023","unstructured":"Julkunen H, Cicho\u0144ska A, Tiainen M, Koskela H, Nybo K, M\u00e4kel\u00e4 V, et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023;14:604.","journal-title":"Nat Commun"},{"key":"2062_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41588-019-0407-x","volume":"51","author":"M Wuttke","year":"2019","unstructured":"Wuttke M, Li Y, Li M, Sieber KB, Feitosa MF, Gorski M, et al. A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet. 2019;51:957\u201372.","journal-title":"Nat Genet"},{"key":"2062_CR21","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.1093\/bioinformatics\/btab665","volume":"37","author":"AE Murphy","year":"2021","unstructured":"Murphy AE, Schilder BM, Skene NG. MungeSumstats: a Bioconductor package for the standardization and quality control of many GWAS summary statistics. Bioinformatics. 2021;37:4593\u201396.","journal-title":"Bioinformatics"},{"key":"2062_CR22","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"81","author":"S Purcell","year":"2007","unstructured":"Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559\u201375.","journal-title":"Am J Hum Genet"},{"key":"2062_CR23","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med. 2017;36:1783\u2013802.","journal-title":"Stat Med"},{"key":"2062_CR24","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1093\/ije\/dyu005","volume":"43","author":"S Burgess","year":"2014","unstructured":"Burgess S. Sample size and power calculations in Mendelian randomization with a single instrumental variable and a binary outcome. Int J Epidemiol. 2014;43:922\u20139.","journal-title":"Int J Epidemiol"},{"key":"2062_CR25","doi-asserted-by":"publisher","first-page":"e34408","DOI":"10.7554\/eLife.34408","volume":"7","author":"G Hemani","year":"2018","unstructured":"Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife. 2018;7:e34408.","journal-title":"Elife"},{"key":"2062_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41588-018-0269-7","volume":"51","author":"D Demontis","year":"2019","unstructured":"Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit\/hyperactivity disorder. Nat Genet. 2019;51:63\u201375.","journal-title":"Nat Genet"},{"key":"2062_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09718-5","volume":"10","author":"T Ge","year":"2019","unstructured":"Ge T, Chen CY, Ni Y, Feng YA, Smoller JW. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat Commun. 2019;10:1776.","journal-title":"Nat Commun"},{"key":"2062_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13742-015-0047-8","volume":"4","author":"CC Chang","year":"2015","unstructured":"Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience. 2015;4:7.","journal-title":"Gigascience"},{"key":"2062_CR29","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1017\/S0033291724000606","volume":"54","author":"E Haan","year":"2024","unstructured":"Haan E, Krebs K, V\u00f5sa U, Brikell I, Larsson H, Lehto K. Associations between attention-deficit hyperactivity disorder genetic liability and ICD-10 medical conditions in adults: utilizing electronic health records in a Phenome-Wide Association Study. Psychol Med. 2024;54:2468\u201381.","journal-title":"Psychol Med"},{"key":"2062_CR30","doi-asserted-by":"crossref","unstructured":"V\u00f5ikar V, Stanford SC. The Open Field Test. In: Harro J, editor. Psychiatric vulnerability, mood, and anxiety disorders: tests and models in mice and rats. p. 9-29. New York, NY: Springer US; 2023.","DOI":"10.1007\/978-1-0716-2748-8_2"},{"key":"2062_CR31","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/7854_2022_342","volume":"57","author":"SC Stanford","year":"2022","unstructured":"Stanford SC. Animal models of ADHD? Curr Top Behav Neurosci. 2022;57:363\u201393.","journal-title":"Curr Top Behav Neurosci"},{"key":"2062_CR32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.33549\/physiolres.932622","volume":"63","author":"M Pravenec","year":"2014","unstructured":"Pravenec M, K\u0159en V, Landa V, Mlejnek P, Musilov\u00e1 A, \u0160ilhav\u00fd J, et al. Recent progress in the genetics of spontaneously hypertensive rats. Physiol Res. 2014;63:S1\u20138.","journal-title":"Physiol Res"},{"key":"2062_CR33","doi-asserted-by":"crossref","unstructured":"Naslund J, Landin J, Hieronymus F, Banote RK, Kettunen P. Anxiolytic-like effects of acute serotonin-releasing agents in zebrafish models of anxiety: experimental study and systematic review. Acta Neuropsychiatr. 2024:1\u201319.","DOI":"10.1017\/neu.2024.44"},{"key":"2062_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/mp.2014.128","volume":"20","author":"AM Stewart","year":"2015","unstructured":"Stewart AM, Ullmann JF, Norton WH, Parker MO, Brennan CH, Gerlai R, et al. Molecular psychiatry of zebrafish. Mol Psychiatry. 2015;20:2\u201317.","journal-title":"Mol Psychiatry"},{"key":"2062_CR35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.tips.2013.12.002","volume":"35","author":"AV Kalueff","year":"2014","unstructured":"Kalueff AV, Stewart AM, Gerlai R. Zebrafish as an emerging model for studying complex brain disorders. Trends Pharmacol Sci. 2014;35:63\u201375.","journal-title":"Trends Pharmacol Sci"},{"key":"2062_CR36","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/s41380-022-01615-6","volume":"27","author":"L Colbourne","year":"2022","unstructured":"Colbourne L, Harrison PJ. Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders. Mol Psychiatry. 2022;27:3904\u201312.","journal-title":"Mol Psychiatry"},{"key":"2062_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1016\/S0024-3205(97)00881-3","volume":"61","author":"S Uchida","year":"1997","unstructured":"Uchida S, Yamada S, Nagai K, Deguchi Y, Kimura R. Brain pharmacokinetics and in vivo receptor binding of 1,4-dihydropyridine calcium channel antagonists. Life Sci. 1997;61:2083\u201390.","journal-title":"Life Sci"},{"key":"2062_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00005344-200308000-00001","volume":"42","author":"BS Huang","year":"2003","unstructured":"Huang BS, Leenen FH. Sympathoinhibitory and depressor effects of amlodipine in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 2003;42:153\u201360.","journal-title":"J Cardiovasc Pharmacol"},{"key":"2062_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1248\/bpb.19.195","volume":"19","author":"K Sugiyama","year":"1996","unstructured":"Sugiyama K, Qu YL, Maruyama K, Hattori K, Watanabe K, Nagatomo T. Slow dissociation of long-acting Ca2+ antagonist amlodipine from 3H-PN200-110 binding sites in membranes of rat hearts and brains. Biol Pharm Bull. 1996;19:195\u20138.","journal-title":"Biol Pharm Bull"},{"key":"2062_CR40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","volume":"6","author":"D Gill","year":"2021","unstructured":"Gill D, Georgakis MK, Walker VM, Schmidt AF, Gkatzionis A, Freitag DF, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.","journal-title":"Wellcome Open Res"},{"key":"2062_CR41","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/S0140-6736(12)62129-1","volume":"381","author":"Cross-Disorder Group of the Psychiatric Genomics Consortium.","year":"2013","unstructured":"Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013;381:1371\u201379.","journal-title":"Lancet"},{"key":"2062_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.neuropharm.2014.03.021","volume":"87","author":"SC Stanford","year":"2014","unstructured":"Stanford SC. Psychostimulants, antidepressants and neurokinin-1 receptor antagonists (\u2018motor disinhibitors\u2019) have overlapping, but distinct, effects on monoamine transmission: the involvement of L-type Ca2+ channels and implications for the treatment of ADHD. Neuropharmacology. 2014;87:9\u201318.","journal-title":"Neuropharmacology"},{"key":"2062_CR43","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67:821\u201370.","journal-title":"Pharmacol Rev"},{"key":"2062_CR44","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1097\/HJH.0000000000003445","volume":"41","author":"D Kerkhofs","year":"2023","unstructured":"Kerkhofs D, Helgers R, Hermes D, Steinbusch HPJ, Van Essen H, Leenders P, et al. Amlodipine limits microglia activation and cognitive dysfunction in aged hypertensive mice. J Hypertens. 2023;41:1159\u201367.","journal-title":"J Hypertens"},{"key":"2062_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1291\/hypres.29.49","volume":"29","author":"Y Hirooka","year":"2006","unstructured":"Hirooka Y, Kimura Y, Nozoe M, Sagara Y, Ito K, Sunagawa K. Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats. Hypertens Res. 2006;29:49\u201356.","journal-title":"Hypertens Res"},{"key":"2062_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-52083-y","volume":"9","author":"HH Park","year":"2019","unstructured":"Park HH, Han MH, Choi H, Lee YJ, Kim JM, Cheong JH, et al. Mitochondria damaged by oxygen glucose deprivation can be restored through activation of the PI3K\/Akt pathway and inhibition of calcium influx by amlodipine camsylate. Sci Rep. 2019;9:15717.","journal-title":"Sci Rep"},{"key":"2062_CR47","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.pbb.2019.05.005","volume":"182","author":"GA Dunn","year":"2019","unstructured":"Dunn GA, Nigg JT, Sullivan EL. Neuroinflammation as a risk factor for attention deficit hyperactivity disorder. Pharmacol Biochem Behav. 2019;182:22\u201334.","journal-title":"Pharmacol Biochem Behav"},{"key":"2062_CR48","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3390\/antiox9111039","volume":"9","author":"JC Corona","year":"2020","unstructured":"Corona JC. Role of oxidative stress and neuroinflammation in attention-deficit\/hyperactivity disorder. Antioxidants. 2020;9:1039.","journal-title":"Antioxidants"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02062-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02062-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T05:03:18Z","timestamp":1747630998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-025-02062-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1038\/s41386-025-02062-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.05.30.24308216","asserted-by":"object"}]},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K\u00c6K, H\u00de, HSS, D\u00deH, and BG are employees of 3Z. HAB, JLC, and MFS are employees of biotx.ai GmbH. The remaining authors have nothing to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}